NasdaqGS:CRNXPharmaceuticals
Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint
In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported by 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints and showed favorable tolerability, biochemical control and symptom relief versus placebo.
This filing extends PALSONIFY’s regulatory footprint beyond its existing US approval and recent positive CHMP...